This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SEPTIN9 / Septin-9 · IHC design guide
Design Immunohistochemistry for SEPTIN9
Plan chromogenic SEPTIN9 IHC in paraffin sections with the catalog antibody at 2–5 μg/ml (datasheet A05279-3). Use the cytoplasmic, occasionally membranous tissue pattern to guide scoring (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SEPTIN9 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic, occasionally membranous (HPA tissue IHC) | |
| Staining pattern | Colon glandular cells: cytoplasmic, occasionally membranous (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A05279-3) | |
| Positive control | Bronchus+4 more · see all | |
| Negative control | Adipose tissue+3 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Tissue-specific isoforms may affect epitope detection (UniProt) | |
| Regulation | TGF-β1/EMT changes actin colocalisation (UniProt) | |
| Isoform / epitope | 8 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended SEPTIN9 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet A05279-3) with the published human brain tissue IHC protocol (PMC5938713).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A05279-3) |
| Fixation | Image fixative and duration unreported (datasheet A05279-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A05279-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A05279-3) |
| Primary antibody | Rabbit anti-SEPTIN9, 2-5 μg/ml (datasheet A05279-3) |
| Primary incubation | Overnight at 4 °C (datasheet A05279-3) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A05279-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SEPTIN9-positive staining in basal cells of bronchus (HPA tissue IHC: High). HPA tissue profile: General cytoplasmic and occasional membranous expression. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 heat retrieval for the catalog antibody (datasheet A05279-3); citrate pH 6.0 is the published alternative (PMC5938713).
Section 2
What Is the Expected SEPTIN9 Staining Pattern?
SEPTIN9 is a cytoplasmic cytoskeletal protein with no transmembrane segment (UniProt Q9UHD8 topology and subcellular location). In paraffin sections, expect mainly cytoplasmic staining, sometimes with a membranous appearance (HPA tissue IHC). HPA reports High staining in several epithelial populations, including colon glandular cells and bronchial basal cells (HPA tissue IHC). The tissue IHC profile is Approved, with medium consistency between staining and RNA data (HPA tissue IHC).
| Cytoplasmic signal in colon glandular cells or bronchial basal cells, with occasional membrane-adjacent accentuation. | This matches HPA's High staining in those cells and its general cytoplasmic, occasional membranous profile (HPA tissue IHC). Membrane-adjacent signal is plausible because SEPTIN9 can concentrate at epithelial cell-cell contacts (UniProt Q9UHD8 subcellular location). Judge the stained cells and compartment together, rather than treating every stained area of the section as equivalent. |
| Strong, predominantly nuclear signal with little cytoplasmic staining. | A nuclear-dominant pattern conflicts with the reported cytoplasmic and cytoskeletal localization (UniProt Q9UHD8 subcellular location; HPA tissue IHC). Treat it as suspect until antibody specificity and detection controls are checked. The supplied sources do not establish a nuclear IHC pattern for SEPTIN9. |
| Prominent signal in adipocytes or cardiomyocytes, while expected epithelial cells stain weakly. | HPA reports SEPTIN9 as Not detected in adipocytes and cardiomyocytes, but High in several specified epithelial populations (HPA tissue IHC). Recheck cell identification and controls; unexpected color may reflect cross-reactivity or endogenous detection activity (general chromogenic IHC practice). These HPA entries describe particular cell types, not whole-tissue negatives. |
| Diffuse color covers stroma, empty spaces, or many cell types without a discernible cytoplasmic pattern. | That distribution does not resemble HPA's cell-associated, generally cytoplasmic profile (HPA tissue IHC). Consider excess primary or detection reagent, incomplete blocking, or inadequate washing (general chromogenic IHC practice). Compare with a matched control section before assigning the diffuse color to SEPTIN9. |
| No signal in the glandular cells of a colon control section. | Colon glandular cells are reported as High by HPA, so their absence of staining makes the run difficult to interpret (HPA tissue IHC). Check section quality, the catalog antibody's IHC-P instructions, retrieval and detection setup, and whether another expected structure stained (general IHC practice). A failed positive control cannot establish that an experimental specimen lacks SEPTIN9. |
💡Expected SEPTIN9 appearanceCall a result positive when identifiable cells show predominantly cytoplasmic chromogen, with occasional membrane-adjacent signal and High staining in an HPA-listed positive population such as colon glandular cells; isolated nuclear color or diffuse acellular color is suspect (HPA tissue IHC; UniProt Q9UHD8 subcellular location; general IHC interpretation).
| Cell type and tissue context | HPA reports High staining in colon, cervix, endometrium, and gallbladder glandular cells, among other listed populations; adipocytes and cardiomyocytes are Not detected (HPA tissue IHC). Select controls by the named cell population within the section. HPA also reports low tissue RNA specificity, which does not make every cell type an equally useful protein-staining control (HPA tissue IHC). |
| Subcellular context | SEPTIN9 is cytoplasmic and cytoskeletal, and lacks a transmembrane segment (UniProt Q9UHD8 topology and subcellular location). HPA describes general cytoplasmic and occasional membranous tissue staining (HPA tissue IHC). Interpret edge accentuation in that context; the supplied evidence does not support treating membrane-only staining as the expected IHC result. |
| Isoforms and antibody epitope | UniProt lists 8 SEPTIN9 isoforms with differential tissue expression (UniProt Q9UHD8 isoforms and tissue specificity). An antibody's epitope determines which isoforms it can detect (general antibody practice). The supplied record gives no epitope or isoform coverage for the catalog antibody, so do not infer isoform identity from staining intensity or distribution. |
| Antibody evidence | HPA042564 is Approved for IHC, whereas no IHC status is supplied for HPA050627; both have Enhanced ICC validation (HPA antibodies). HPA's tissue profile has medium staining-to-RNA consistency (HPA tissue IHC). Use these ratings as context for interpreting a pattern, not as proof that every stained cell is specific. |
| IF/ICC Q&A: Where should SEPTIN9 fluorescence appear? | Mainly along actin filaments, with additional localization to microtubules, the cytokinetic bridge, and primary cilium (HPA subcellular ICC-IF). This is an ICC-IF observation; it does not require resolving those structures in chromogenic paraffin sections. UniProt also places SEPTIN9 in the cytoplasmic cytoskeleton (UniProt Q9UHD8 subcellular location). |
| Retrieval and fixation evidence | No target-specific fixation sensitivity or retrieval condition is established by the supplied UniProt and HPA records. Follow the catalog antibody's IHC-P instructions and evaluate the positive control when setting up a run (general IHC practice). Do not attribute a positive or negative tissue result to a SEPTIN9-specific fixation effect on this evidence. |
| Situation | Likely cause | Next action |
|---|---|---|
| Colon glandular positive control is blank. | Possible run-level retrieval, primary-antibody, or detection failure (general IHC practice); colon glandular cells are High in HPA tissue IHC. | Verify the catalog antibody's IHC-P conditions, reagent sequence, and detection activity; repeat with a control section containing identifiable colon glands (general IHC practice). Interpret experimental negatives only after the positive control works. |
| Signal is mainly nuclear. | The compartment disagrees with cytoplasmic and cytoskeletal localization (UniProt Q9UHD8 subcellular location; HPA tissue IHC). Nonspecific staining or detection artifact is possible (general IHC practice). | Check a matched negative control and a known-positive cell population, then review antibody concentration and detection steps (general IHC practice). Require a reproducible cytoplasmic pattern before calling the section positive. |
| Adipocytes or cardiomyocytes stain strongly. | Those named cell types are Not detected in HPA tissue IHC. Cross-reactivity or endogenous detection activity may contribute to unexpected chromogen (general IHC practice). | Confirm cell identity, compare a primary-omission control, and check the detection blocking steps (general chromogenic IHC practice). Do not label an entire adipose or heart section negative solely from HPA's cell-type entries. |
| A broad brown haze obscures cell boundaries. | Diffuse background can arise from excess reagent, incomplete blocking, or insufficient washing (general chromogenic IHC practice); it obscures HPA's mainly cytoplasmic pattern (HPA tissue IHC). | Inspect a primary-omission control, review blocking and wash steps, and optimize antibody concentration under the catalog IHC-P workflow (general IHC practice). Score only localized cellular signal that remains distinguishable from background. |
| One epithelial population stains while another is faint. | HPA assigns levels to specific cells and reports medium staining-to-RNA consistency (HPA tissue IHC); UniProt reports different tissue expression among SEPTIN9 isoforms (UniProt Q9UHD8 tissue specificity). | Record tissue, cell type, compartment, and intensity separately; compare each with its own HPA entry (HPA tissue IHC). Avoid inferring a particular isoform because antibody epitope coverage is not supplied. |
| Only a thin cell-edge line is visible. | Occasional membranous staining is reported by HPA, and SEPTIN9 can concentrate at epithelial contacts (HPA tissue IHC; UniProt Q9UHD8 subcellular location). An edge-only result is less complete than HPA's general cytoplasmic profile. | Inspect the same cells for cytoplasmic signal and compare with a positive control and negative control (general IHC practice). Record the edge pattern separately if cytoplasmic staining cannot be confirmed. |
Experiment evidence
IHC & IF images showing SEPTIN9 staining
A05279-3 · IHCIHC analysis of MSF/SEPTIN9 using anti-MSF/SEPTIN9 antibody (A05279-3). MSF/SEPTIN9 was detected in a paraffin-embedded section of human bre
A05279-3 · IHCIHC analysis of MSF/SEPTIN9 using anti-MSF/SEPTIN9 antibody (A05279-3). MSF/SEPTIN9 was detected in a paraffin-embedded section of human liv
A05279-3 · IFIF analysis of SEPTIN9 using anti-SEPTIN9 antibody (A05279-3). SEPTIN9 was detected in a paraffin-embedded section of human liver cancer tis
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000184640-SEPTIN9/tissue/cerebral+cortex#imid_11312575
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000184640-SEPTIN9/tissue/colon#imid_11318781
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000184640-SEPTIN9/tissue/liver#imid_11318766
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000184640-SEPTIN9/tissue/kidney#imid_11318775
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA042564; green = SEPTIN9, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA042564; green = SEPTIN9, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SEPTIN9 IHC & IF
🧪Run bronchus first and score its basal cells, which show High SEPTIN9 staining (HPA: High in bronchus basal cells). Use adipose tissue as the negative tissue, focusing on adipocytes (HPA: Not detected in adipocytes); on the bronchus slide, cells without specific cytoplasmic staining should remain at background, although HPA does not identify a confirmed negative cell type there (UniProt Q9UHD8: cytoplasm, cytoskeleton).
Positive control tissue: Bronchus (Basal cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SEPTIN9 in A-431, U-251MG, U2OS, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), with annotated localisation: Actin filaments (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; a rabbit IgG isotype control matched to the primary antibody’s clonality; and SEPTIN9-knockout material as a biological negative (caption: rabbit primary antibody). For chromogenic detection, block endogenous peroxidase and check whether any signal in the bronchus persists in the no-primary control (caption: peroxidase secondary and DAB chromogen).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A05279-3 paraffin-section caption does not state the fixative (selected-SKU IHC caption). That caption uses heat retrieval in EDTA, pH 8.0, but it does not establish that retrieval is required under other conditions (selected-SKU IHC caption). Whether frozen sections or IF are easier is unreported; in bronchus, inspect luminal mucus and inflammatory cells for background when interpreting basal-cell staining (HPA: High in bronchus basal cells; caption: DAB detection).
HPA tissue IHC evidence for SEPTIN9
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | Basal cells | High | Protein (IHC) | HPA → |
| Cervix | Glandular cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Endometrium | Glandular cells | High | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
| Skeletal muscle | Myocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SEPTIN9 IHC Tips
Troubleshoot SEPTIN9 chromogenic IHC using the documented paraffin-section workflow, tissue staining patterns, and intracellular localisation (datasheet A05279-3; HPA; UniProt Q9UHD8).
Why is SEPTIN9 staining weak after antigen retrieval?
Use heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A05279-3). The demonstrated breast cancer section then received 10% goat serum and 2 μg/ml primary antibody overnight at 4°C, providing a starting workflow for troubleshooting weak chromogenic signal (datasheet A05279-3). If staining remains weak, verify heating consistency, section adhesion, and the positive-control compartment before changing retrieval conditions (standard IHC practice; HPA: general cytoplasmic expression). If needed, compare a second retrieval condition on adjacent sections while holding antibody concentration and detection constant, and reject conditions that increase diffuse background or tissue damage (standard IHC practice).
Can fixation explain weak SEPTIN9 staining in my paraffin sections?
The selected image documents a paraffin-embedded breast cancer section but does not state its fixative, so target-specific fixation sensitivity is unknown (datasheet A05279-3). Record the actual fixative, fixation interval, processing history, and section age for each specimen before comparing chromogenic intensity (standard IHC practice). Apply the documented EDTA pH 8.0 retrieval and 2 μg/ml primary incubation overnight at 4°C to a reference section when evaluating a new batch (datasheet A05279-3). Compare matched tissues processed together, assess preservation and edge staining, and interpret any fixation-dependent change as an empirical result rather than an established SEPTIN9 property (standard IHC practice).
Which staining compartments are plausible for SEPTIN9 in tissue IHC?
Prioritize cytoplasmic staining, with occasional membranous staining, when reviewing chromogenic sections (HPA: general cytoplasmic and occasional membranous expression). SEPTIN9 is a cytoskeletal protein without a transmembrane segment, and septin complexes associate with actin filaments, microtubules, and cellular membranes (UniProt Q9UHD8 subcellular location, topology, and subunit). HPA cell imaging also places the protein mainly on actin filaments and additionally on microtubules, the cytokinetic bridge, and the primary cilium; these are localization context, not separately validated tissue-IHC patterns (HPA: subcellular). Score cell-associated cytoplasmic signal before treating an isolated nuclear or diffuse luminal DAB deposit as specific (HPA: tissue profile; standard IHC practice).
Could a negative section reflect isoform or epitope coverage?
SEPTIN9 has 8 annotated isoforms, and their expression can differ by tissue, so a negative chromogenic section does not establish absence of every isoform (UniProt Q9UHD8 isoforms and tissue specificity). The supplied tissue-IHC caption identifies antibody A05279-3 but gives no mapped epitope or isoform coverage; do not assign that antibody isoform specificity from staining alone (datasheet A05279-3). SEPTIN9 includes a septin-type G domain at residues 295–567 and reported phosphorylated residues near its N terminus, but neither fact locates this antibody's epitope (UniProt Q9UHD8 domains and modified residues). Resolve discordance with documented epitope information, an independent antibody, or an orthogonal assay on matched material (standard IHC practice).
How should I investigate a discordant SEPTIN9 IF result?
Treat IF/ICC as a separate assay and compare its pattern with chromogenic IHC after checking assay-specific controls (standard IHC/IF practice). Multiplex SEPTIN9 with a marker for the expected cell type, such as a validated epithelial marker when assessing epithelial compartments, and include single-color controls to check bleed-through (HPA: high staining in several epithelial cell populations; standard IF practice). Choose spectrally separated fluorophores and channels with low tissue autofluorescence, verifying the background in an unstained section (standard IF practice). Because SEPTIN9 is cytoplasmic and lacks a transmembrane segment, optimize permeabilisation for intracellular epitope access while checking that filament morphology remains intact (UniProt Q9UHD8 subcellular location and topology; standard IF practice).
How do I separate SEPTIN9 signal from DAB background?
Compare a no-primary control with the complete chromogenic reaction to identify detection-system deposits, and inspect folds, edges, necrosis, and pigment under the same microscope settings (standard IHC practice). In the documented paraffin-section example, blocking used 10% goat serum, followed by 2 μg/ml rabbit primary overnight at 4°C and a peroxidase-based DAB readout (datasheet A05279-3). Add a peroxidase block and titrate primary antibody or detection exposure if widespread staining persists; these are general workflow adjustments, not SEPTIN9-specific validation (standard IHC practice). Compare background with cell-associated cytoplasmic signal, the principal tissue pattern, before accepting a weak positive call (HPA: general cytoplasmic expression; standard IHC practice).
How should I score SEPTIN9 across heterogeneous sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the region and cell population before scoring, then report the percentage of positive cells and an intensity-weighted H-score for cytoplasmic DAB staining (HPA: general cytoplasmic expression; standard IHC practice). If spatial burden matters, report positive cells per mm² of viable tissue and normalize to the number of evaluable cells or viable area, respectively (standard IHC practice). Keep retrieval, 2 μg/ml primary concentration, overnight 4°C incubation, and DAB development settings consistent across the batch when following the workflow (datasheet A05279-3; standard IHC practice). Stratify scores by cell type because HPA reports high epithelial staining in several tissues but no detectable signal in some other cell populations (HPA: tissue IHC).
When should I doubt a positive SEPTIN9 IHC result?
Expect predominantly cell-associated cytoplasmic signal, sometimes near membranes, and check whether the stained cell type fits the tissue context (HPA: tissue IHC profile). HPA reports high staining in bronchial basal cells and colonic glandular cells, while adipocytes and skeletal-muscle myocytes were not detected; use these as contextual references, not absolute specificity controls (HPA: tissue IHC). Doubt isolated nuclear staining, section-edge enhancement, necrotic deposits, or signal reproduced in a no-primary or peroxidase-control section (UniProt Q9UHD8 subcellular location; standard IHC practice). Because HPA rates its tissue staining Approved with only medium RNA agreement, confirm consequential calls with an independent reagent or orthogonal measurement (HPA: reliability; standard IHC practice).
Boster reagents
Best SEPTIN9 / Septin-9 IHC Antibodies
A05279-3 has IHC images from paraffin-embedded human breast, liver, and lung cancers and mouse lymphaden tissue; IF images show paraffin-embedded human breast and liver cancers (catalog image captions).
Real IHC data
Anti-MSF/SEPTIN9 Antibody ®
Cat # A05279-3
A05279-3 is listed for IHC and IF in human and mouse samples (catalog applications and reactivity). Its IHC captions document paraffin-embedded human breast, liver, and lung cancers and mouse lymphaden tissue; its IF captions document paraffin-embedded human breast and liver cancers (catalog image captions).
Which to pick: Choose A05279-3 for tissue IHC on paraffin sections, supported by its own IHC captions; the fixative is unreported (catalog IHC image captions). Choose A05279-3 for tissue IF based on its IF captions; ICC validation is unreported (catalog applications and IF image captions). For human and mouse work, A05279-3 lists both species as reactive and has IHC images for each; it is a rabbit antibody, with clonality unreported (catalog reactivity, host, and IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9UHD8 (SEPT9_HUMAN, Septin-9).
- Human Protein Atlas. SEPTIN9 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. SEPTIN9 subcellular location (ICC-IF): Mainly localized to the actin filaments. In addition localized to the microtubules, cytokinetic bridge and primary cilium..
- Human Protein Atlas. SEPTIN9 antibody validation summary (2 antibodies).
- Repression of Septin9 and Septin2 suppresses tumor growth of human glioblastoma cells. Cell death & disease 2018 — PMC5938713.
- SEPT9 as a therapeutic target for enhancing radiotherapy efficacy in esophageal squamous cell carcinoma. Discover oncology 2026 — PMC12868481.
- PubMed PMID:10339604 — UniProt-cited evidence.
- PubMed PMID:10987277 — UniProt-cited evidence.
- PubMed PMID:10673329 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SEPTIN9 (Septin-9). Expected localisation Cytoplasmic, occasionally membranous (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A05279-3). Validated IHC antibody: A05279-3 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bronchus (Basal cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A05279-3); 2. Fixation: Image fixative and duration unreported (datasheet A05279-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A05279-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A05279-3); 8. Primary antibody: Rabbit anti-SEPTIN9, 2-5 μg/ml (datasheet A05279-3); 9. Primary incubation: Overnight at 4 °C (datasheet A05279-3). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Tissue-specific isoforms may affect epitope detection (UniProt); Isoform / epitope: 8 isoforms; epitope coverage is unspecified (UniProt); Regulation: TGF-β1/EMT changes actin colocalisation (UniProt). Evidence: UniProt Q9UHD8, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the actin filaments. In addition localized to…, Datasheet A05279-3, PMC5938713. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SEPTIN9/immunohistochemistry-ihc-guide.